Table 4.
Number | Core Recommendations | Totala |
---|---|---|
32 | Transform the regulatory framework for innovative veterinary medicines | 14 |
39 | Develop new approaches to improve the benefit-risk assessment of veterinary medicinal products | 8 |
37 | Collaborate with stakeholders to modernize veterinary pharmacoepidemiology and pharmacovigilance | 6 |
33 | Reinforce and further embed application of the 3Rs principles | 4 |
40 | Continue to promote the responsible use of antimicrobials and their alternatives | 4 |
43 | Promote and support development of veterinary vaccines | 4 |
34 | Facilitate implementation of novel manufacturing models | 3 |
41 | Coordinate Network activities to improve data collection on antimicrobial use in animals | 3 |
44 | Develop network-led partnerships with academia to undertake fundamental research in strategic areas of regulatory science | 3 |
45 | Leverage collaborations between academia and network scientists to address rapidly emerging regulatory science research questions | 3 |
36 | Apply the latest scientific principles to the assessment of the safety of residues of veterinary medicines | 2 |
46 | Identify and enable access to the best expertise across Europe and internationally | 2 |
47 | Disseminate and exchange knowledge, expertise, and innovation across the network and to its stakeholders | 2 |
35 | Update Environmental Risk Assessments in line with the latest scientific knowledge | 1 |
38 | Develop new and improved communication and engagement channels and methods to reach out to stakeholders | 0 |
42 | Engage with stakeholders to minimize the risks of anti-parasitic resistance | 0 |
Total times chosen as first, second, or third most important.